Placebo matching BI 3000202

DRUG2 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim

Conditions

HealthySystemic lupus erythematosus

Phase 1

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

CompletedNCT05945888

Boehringer IngelheimHealthy

Start: 2023-07-25End: 2023-11-13Updated: 2026-06-08

Phase 2

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

Not yet recruitingCTIS2025-523488-39-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Systemic lupus erythematosus

Target: 7Updated: 2026-05-04